Geron (NASDAQ:GERN) Trading 4.7% Higher

Geron Co. (NASDAQ:GERN - Get Free Report) shares shot up 4.7% on Wednesday . The stock traded as high as $3.78 and last traded at $3.75. 961,135 shares changed hands during trading, a decline of 91% from the average session volume of 11,179,831 shares. The stock had previously closed at $3.58.

Analysts Set New Price Targets

Several brokerages have recently weighed in on GERN. Needham & Company LLC reiterated a "buy" rating and set a $5.00 price target on shares of Geron in a research report on Thursday, April 11th. The Goldman Sachs Group upped their price target on Geron from $4.00 to $5.00 and gave the company a "buy" rating in a research report on Friday, March 15th. Finally, Wedbush reiterated an "outperform" rating and set a $6.00 price target on shares of Geron in a research report on Wednesday, April 10th.

Geron Stock Performance

The company has a quick ratio of 3.16, a current ratio of 3.16 and a debt-to-equity ratio of 0.14. The company's 50-day moving average is $2.64 and its two-hundred day moving average is $2.20. The company has a market capitalization of $2.01 billion, a P/E ratio of -11.33 and a beta of 0.62.

Geron (NASDAQ:GERN - Get Free Report) last posted its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.01. The company had revenue of $0.02 million for the quarter, compared to analysts' expectations of $0.06 million. Geron had a negative net margin of 77,691.14% and a negative return on equity of 63.33%. Geron's revenue for the quarter was down 77.7% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.10) earnings per share. Equities analysts anticipate that Geron Co. will post -0.34 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of GERN. PNC Financial Services Group Inc. purchased a new stake in Geron in the second quarter worth approximately $32,000. Cerity Partners LLC purchased a new stake in Geron in the fourth quarter worth approximately $26,000. CIBC Asset Management Inc purchased a new stake in Geron in the fourth quarter worth approximately $27,000. Pathstone Family Office LLC purchased a new stake in Geron in the third quarter worth approximately $26,000. Finally, Creative Planning purchased a new stake in Geron in the third quarter worth approximately $26,000. 73.71% of the stock is currently owned by institutional investors.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.